Digital Therapeutic for Schizophrenia
A new digital therapeutic, CT-155, has shown promise in reducing negative symptoms of schizophrenia.
CT-155 is a smartphone app that uses adaptive goal-setting technique to deliver psychosocial interventions.
- Developed by Boehringer Ingelheim and Click Therapeutics
- First experimental prescription digital therapy with good tolerability and no significant adverse events
A prescription digital therapy has demonstrated that it can reduce the negative symptoms of schizophrenia.
An estimated 24 million people worldwide have schizophrenia, according to the World Health Organization, characterized by persistent delusions and hallucinations.
Author's summary: Digital therapeutic CT-155 reduces schizophrenia symptoms.